Phompradit Papichaya, Muhamad Poonuch, Chaijaroenkul Wanna, Na-Bangchang Kesara
Graduate program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University (Rangsit Campus), Patumthani 12121, Thailand.
Thailand center of Excellence on Drug Discovery and Development, Thammasat University (Rangsit campus), Patumthani 12121, Thailand.
Acta Trop. 2014 Nov;139:77-83. doi: 10.1016/j.actatropica.2014.06.015. Epub 2014 Jul 5.
The genetic polymorphisms of the candidate markers of antimalarial drug resistance pfcrt, pfmdr1, pfatp6, and pfmrp1 were investigated in relationship with in vitro susceptibility of Plasmodium falciparum isolates and clinical response following artesunate (AS)-mefloquine (MQ) combination in 21 and 27 samples obtained from patients with recrudescence and adequate clinical response, respectively. MQ (21.0 vs. 49.9nM) and AS (1.6 vs. 2.8nM) IC50 values (concentrations that inhibit parasite growth by 50%) were significantly higher in isolates collected from patients with recrudescence. Furthermore, a significantly higher MQ IC50 was found in isolates from patients with recrudescence that carried pfmrp1 mutations at amino acid residues 191Y, 437A, and 876V. For AS sensitivity, a significant association was also detected in isolates from patients with recrudescence that carried gene mutations at amino acid residues 437A and 876V. MQ IC50 of the isolates with recrudescence which carried ≥4 pfmdr1 gene copies was significantly higher than that carrying only one gene copy. In addition, a significantly higher proportion of isolates carrying one gene copy was detected in the group with adequate clinical response compared with recrudescence. Results from this limited sample size suggested the potential link between pfmdr1 gene copy number and pfmrp1 gene mutation, in vitro parasite susceptibility, and AS-MQ treatment response.
研究了抗疟药物耐药性候选标志物pfcrt、pfmdr1、pfatp6和pfmrp1的基因多态性,及其与恶性疟原虫分离株体外敏感性的关系,以及分别从复发患者和有充分临床反应的患者中获取的21份和27份样本在青蒿琥酯(AS)-甲氟喹(MQ)联合用药后的临床反应。复发患者分离株的MQ(21.0对49.9nM)和AS(1.6对2.8nM)半数抑制浓度(IC50值,即抑制寄生虫生长50%的浓度)显著更高。此外,在复发患者分离株中,携带pfmrp1基因第191位氨基酸Y、第437位氨基酸A和第876位氨基酸V突变的分离株的MQ IC50显著更高。对于AS敏感性,在复发患者分离株中携带第437位氨基酸A和第876位氨基酸V基因突变的分离株也检测到显著关联。携带≥4个pfmdr1基因拷贝的复发分离株的MQ IC50显著高于仅携带一个基因拷贝的分离株。此外,与复发组相比,在有充分临床反应的组中检测到携带一个基因拷贝的分离株比例显著更高。这个有限样本量的研究结果表明pfmdr1基因拷贝数与pfmrp1基因突变、体外寄生虫敏感性以及AS-MQ治疗反应之间可能存在联系。